LecanemabdonanemabAustraliaAlzheimer’s diseaseAndrews et alAlzheimer
…ave not translated into a truly substantial functional benefit. Lecanemab, for example, slowed decline on the clinical dementia rating-su…
5articles mentioning drugs
7drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: donanemab ×
donanemab
This drug is selected. Its supporting articles are shown below.
Articles mentioning donanemab
5 articles · page 1 of 1donanemabAducanumablecanemabAlzheimer’s diseaseFDAADMCImild cognitive impairmentU.S. Food and Drug AdministrationFDA-approved+2 more
…pproved in 2021 but then withdrawn in 2024, while lecanemab and donanemab were approved in 2023/2024. These are the first therapies to sh…
97.2%
donepezilgalantaminerivastigminememantinedonanemablecanemabAlzheimer’s diseaseacetylcholinesterase inhibitorsAD
…ptomatic treatments, including acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and the N-methyl-D-aspartate (N…
LecanemabdonanemabNICEADFDANottingham University Hospitals NHS TrustDMTsAlzheimer’s diseaseMCIMild Cognitive Impairment
…e-modifying therapies (DMTs) in early Alzheimer’s disease (AD). Lecanemab and donanemab have received FDA approval and could be introduce…
donanemablecanemabAlzheimer’s diseaseADRoyal Melbourne Hospital
…ning FLAIR and SWI sequences. Twenty patients were eligible for donanemab or lecanemab (11.7%) based on reported trial criteria. CMBs cou…